Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans.
It is a $89.3B healthcare company. Revenue grew 6.3% over the last year, it keeps 2¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 18.0× earnings — around the middle of its own history.
- Website
- elevancehealth.com
- Location
- Indianapolis, IN
- Employees
- 97 100
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation, quality and moat; Growth, Profitability and Health lag behind.
Valuation77
- P/E vs own history52th pct · 12/25
- FCF yield7.0% · 20/25
- P/S0.4x · 25/25
- EV/EBITDA14.1x · 20/25
Growth44
- Revenue CAGR9.5% · 12/25
- Net income CAGR-1.9% · 0/25
- EPS CAGR ~5Y6.8% · 12/25
- Fwd implied growth29.3% · 20/25
Profitability35
- ROIC14.4% · 12/25
- ROE11.2% · 12/25
- Net margin2.5% · 6/25
- Operating margin3.6% · 5/25
Health46
- Altman Z1.33 · 3/25
- Current ratio0.23 · 0/25
- Interest coverage5.8x · 18/25
- Net cash / debtNet cash · 25/25
Quality85
- Piotroski F6/9 · 15/25
- Beneish M-2.38 · 20/25
- FCF conversion127% · 25/25
- Margin stabilityσ 1.2% · 25/25
Moat87
- ROIC >12% years10/10 yrs · 25/25
- Median gross margin91.7% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 2.8% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- Q3 2026Insiders3 open-market insider purchases~4K shares bought by insiders
- FY2021FinancialBest year on record$6.10B net income
- FY2019FinancialRevenue crossed $100B$104B for the year
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $50B$84.9B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- Net cash position after subtracting debt from cash
- Interest covered 5.8× by operating earnings
Watch-outs
- Altman Z-Score 1.33 — elevated financial-distress risk
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+6.3% YoY
- Profitable — makes more than it spends$4.96B TTM
- Profit growing — earnings are higher than last year+1.3% YoY
- Generates cash — cash left after running and investing$6.29B TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$89.3B market cap
- Not printing shares — share count not ballooning — you keep your slice-10.9% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 1.3 — distress
- Pays a dividend — returns cash to shareholdersyield 1.68%
- Valuation not extreme — price not wildly above earningsP/E 18.0
Peer comparisonElevance Health, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ELV this company | $89.3B | 18.0 | +6.3% | 2.5% | Strained |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ELV vs LLY · ELV vs JNJ · ELV vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ELV
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ELV on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $411.70 · market cap $89.3B.